Cigarra COVID-19 Variant BA.3.2: Risks and Spread Among Children

A new Omicron-related subvariant of COVID-19, officially designated as BA.3.2 and nicknamed Cicada, is drawing attention from global health experts due to its specific impact on children. While COVID-19 levels have remained low in many regions, this heavily mutated strain is showing a distinct pattern of infection that differs from previous versions of the virus.

The variant has been identified through global and United States monitoring systems. According to the U.S. Centers for Disease Control and Prevention (CDC), BA.3.2 was detected in nasal swabs from four travelers, clinical samples from five patients, and three airplane wastewater samples. By early February 2026, the CDC had also identified the variant in wastewater samples across 25 U.S. States.

Beyond the United States, the Cicada variant has been spotted in 23 countries. The nickname Cicada refers to the insect’s biological habit of disappearing and reemerging after years underground, reflecting the variant’s status as a sleeper branch of the Omicron family tree.

Increased Vulnerability in Children

The most significant concern regarding BA.3.2 is its behavior in younger populations. Early observations suggest the variant may be significantly more infectious in children, with some reports indicating they could be up to five times more vulnerable to infection compared to previous strains.

This represents a shift from earlier phases of the pandemic when children were relatively less affected. Experts believe several factors contribute to this increased risk, including:

• Higher transmissibility of the BA.3.2 variant.
• Weaker prior immunity in children.
• Increased exposure within social settings and schools.
• Potential changes in how the virus interacts with younger immune systems.

While the symptoms in children remain largely similar to those of earlier strains, doctors have noted that these symptoms may appear more intensely or more frequently.

Severity and Vaccine Evasion

Despite the higher rate of infection among children, scientists indicate that the variant is not causing more severe disease in either children or adults. The CDC is currently evaluating the variant’s clinical impact, transmissibility, and ability to bypass prior immunity.

The BA.3.2 variant possesses over 70 spike protein mutations. These mutations may allow the virus to escape antibodies developed from previously administered vaccines or prior infections. However, health experts still believe that current vaccines offer some level of protection.

Public Health Response and Guidance

The World Health Organization (WHO), along with the Ministry of Health and Family Welfare and the Indian Council of Medical Research (ICMR), have stated that there is no immediate threat to public life. Because the variant has not significantly increased the severity of the illness, some scientists suggest it is not yet clear if updated vaccine shots are necessary.

To mitigate the risk of infection, health experts recommend adhering to general health advisory practices. These include:

• Maintaining hand washing and general hygiene.
• Wearing masks in public places.
• Obtaining booster vaccinations to strengthen immunity.

Monitoring the spread of BA.3.2 continues to provide valuable data for scientists attempting to predict the evolution of the virus and its interaction with the human immune system.